Ophthalmology · 2026
Nonsteroidal Anti-inflammatory Drug Use and the Risk of Age-Related Macular Degeneration: Insights from a Multicenter Cohort Analysis.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hsu Alan Y, Kuo Hou-Ting, Liu De-Yi, Hsia Ning-Yi, Lai Chun-Ting, Chiang Chun-Chi, Lin Chun-Ju, Shao Yi-Ching, Chen Huan-Sheng, Wu Bing-Qi, Tseng Hsin, Hsu Ho-Che, Wang Yu-Hsun, Bair Henry, Tsai Yi-Yu, Hsu Min-Yen, Wei James Cheng-Chung
Аннотация
PURPOSE: To investigate the effect of nonsteroidal anti-inflammatory drug (NSAID) use and the risk of age-related macular degeneration (AMD).
DESIGN: Retrospective cohort study using a de-identified multicenter electronic medical records database.
PARTICIPANTS: This study included patients who received prescriptions for NSAIDs and individuals who did not to assess for the effects of NSAID prescriptions on future AMD risk.
METHODS: Data from the TriNetX database between January 1, 2015, and December 31, 2024, were used to identify patients who were prescribed NSAIDs with no prior history of AMD. The NSAID patient cohort was propensity score-matched in a 1:1 ratio with a control group of randomly selected patients without a history of NSAID use, based on age, sex, race, and selected comorbidities of interest, including smoking and other common adult comorbidities that potentially could affect future AMD risk.
MAIN OUTCOME MEASURES: Cumulative incidence and hazard ratio (HR) of AMD.
RESULTS: Six hundred thirty-four thousand seven hundred ninety-four patients who were prescribed NSAIDs (mean ± standard deviation age, 59.93 ± 11.95 years) and 634 794 patients who were not prescribed NSAIDs (mean ± standard deviation age, 59.68 ± 12.15 years) were recruited. Among NSAID users, decreased risk of AMD development was seen at 6 months (HR, 0.31; 95% confidence interval [CI], 0.27-0.36), 1 year (HR, 0.36; 95% CI, 0.33-0.39), 3 years (HR, 0.42; 95% CI, 0.40-0.44), and 5 years (HR, 0.48; 95% CI, 0.47-0.50) after the index date compared with nonusers. A protective effect against AMD development was observed (HR, 0.58; 95% CI, 0.56-0.59) among NSAID users compared with nonusers. A protective effect against AMD development was observed among patients who were prescribed aspirin (HR, 0.72; 95% CI, 0.69-0.75) and those prescribed nonselective cyclooxygenase-2 inhibitors (HR, 0.41; 95% CI, 0.36-0.46) compared with their respective nonusers. A decreased risk of AMD was observed for both nonexudative (HR, 0.56; 95% CI, 0.55-0.58) and exudative (HR, 0.62; 95% CI, 0.59-0.65) AMD subtypes after index NSAID prescription compared with nonusers.
CONCLUSIONS: A protective effect against future AMD development was suggested among patients prescribed NSAIDs compared with nonusers.
FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
DESIGN: Retrospective cohort study using a de-identified multicenter electronic medical records database.
PARTICIPANTS: This study included patients who received prescriptions for NSAIDs and individuals who did not to assess for the effects of NSAID prescriptions on future AMD risk.
METHODS: Data from the TriNetX database between January 1, 2015, and December 31, 2024, were used to identify patients who were prescribed NSAIDs with no prior history of AMD. The NSAID patient cohort was propensity score-matched in a 1:1 ratio with a control group of randomly selected patients without a history of NSAID use, based on age, sex, race, and selected comorbidities of interest, including smoking and other common adult comorbidities that potentially could affect future AMD risk.
MAIN OUTCOME MEASURES: Cumulative incidence and hazard ratio (HR) of AMD.
RESULTS: Six hundred thirty-four thousand seven hundred ninety-four patients who were prescribed NSAIDs (mean ± standard deviation age, 59.93 ± 11.95 years) and 634 794 patients who were not prescribed NSAIDs (mean ± standard deviation age, 59.68 ± 12.15 years) were recruited. Among NSAID users, decreased risk of AMD development was seen at 6 months (HR, 0.31; 95% confidence interval [CI], 0.27-0.36), 1 year (HR, 0.36; 95% CI, 0.33-0.39), 3 years (HR, 0.42; 95% CI, 0.40-0.44), and 5 years (HR, 0.48; 95% CI, 0.47-0.50) after the index date compared with nonusers. A protective effect against AMD development was observed (HR, 0.58; 95% CI, 0.56-0.59) among NSAID users compared with nonusers. A protective effect against AMD development was observed among patients who were prescribed aspirin (HR, 0.72; 95% CI, 0.69-0.75) and those prescribed nonselective cyclooxygenase-2 inhibitors (HR, 0.41; 95% CI, 0.36-0.46) compared with their respective nonusers. A decreased risk of AMD was observed for both nonexudative (HR, 0.56; 95% CI, 0.55-0.58) and exudative (HR, 0.62; 95% CI, 0.59-0.65) AMD subtypes after index NSAID prescription compared with nonusers.
CONCLUSIONS: A protective effect against future AMD development was suggested among patients prescribed NSAIDs compared with nonusers.
FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.